<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031833</url>
  </required_header>
  <id_info>
    <org_study_id>MB-70007</org_study_id>
    <nct_id>NCT04031833</nct_id>
  </id_info>
  <brief_title>Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)</brief_title>
  <acronym>EnACT</acronym>
  <official_title>Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matinas BioPharma Nanotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Matinas BioPharma Nanotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as two sequential trials. The first is a phase I open label trial to
      evaluate the safety and tolerability of MAT2203. The maximal tolerated and non-toxic daily
      dose,will then be moved forward into a multi-day safety trial. The Phase II trial will
      investigate toxicity and early fungicidal activity (EFA) of MAT2203 with flucytosine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cryptococcal meningitis has emerged as one of the most frequent and deadly opportunistic
      infections in HIV patients. Historically, amphotericin B (AMB) has been considered the &quot;gold
      standard&quot; in antifungal treatments due to its broad spectrum of activity and lack of
      emergence of resistance. However, the use of AMB is limited by side effects, including
      nephrotoxicity, anemia, and infusion-related reactions. MAT2203 or encochleated oral
      amphotericin B (cAMB) is a lipid nano-crystal formulation designed for targeted oral delivery
      of the antifungal drug AMB for treatment of fungal and parasitic infections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase I: Persons in Uganda without meningitis or active infections Phase II: HIV-infected persons in Uganda with cryptococcal meningitis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Highest dose tolerated without inducing vomiting</measure>
    <time_frame>7 days</time_frame>
    <description>Proportion of cAMB daily dose received and tolerated without vomiting within 30 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of fungicidal activity</measure>
    <time_frame>2 weeks</time_frame>
    <description>CSF early fungicidal activity (EFA) during 2-week induction therapy</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>Phase 1a single ascending dose study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b multiple day dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 safety and tolerability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAT2203</intervention_name>
    <description>Encochleated amphotericin B</description>
    <arm_group_label>Phase 1a single ascending dose study</arm_group_label>
    <arm_group_label>Phase 1b multiple day dosing</arm_group_label>
    <arm_group_label>Phase 2 safety and tolerability</arm_group_label>
    <other_name>oral amphotericin B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphotericin B</intervention_name>
    <description>Intravenous amphotericin B</description>
    <arm_group_label>Phase 2 safety and tolerability</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phase 1:

               -  Age &gt;18 years

               -  Calculated creatinine clearance &gt;70 mL/min/1.73 m2 (measured within 3 months)

               -  Written informed consent

        Phase 2:

          -  Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG)

          -  Ability and willingness to provide informed consent

          -  Willing to receive protocol-specified lumbar punctures

        Exclusion Criteria:

          -  Phase 1:

               -  Symptomatic Current illness

               -  Known significant, untreated health problem

               -  Inability to take enteral medicine

               -  Pregnant or breast feeding

               -  Receiving amphotericin B therapy in past 90 days

          -  Phase 2:

               -  Presenting Glasgow Coma Scale (GCS) &lt; 15

               -  Received 3 or more doses of IV amphotericin therapy within last 30 days

               -  Inability to take enteral (oral or nasogastric) medicine

               -  Cannot or unlikely to attend regular clinic visits

               -  Pregnancy or breastfeeding

               -  Receiving chemotherapy or corticosteroids

               -  Suspected Paradoxical immune reconstitution inflammatory syndrome (IRIS)

               -  Recent initiation of HIV therapy or ART class switch (within 2 weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Theresa Matkovits, Ph.D</last_name>
    <phone>862 812-1436</phone>
    <email>tmatkovits@matinasbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Boulware, MD</last_name>
    <phone>612 626-9546</phone>
    <email>boulw001@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Infectious Disease Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Meya, MD</last_name>
      <email>david.meya@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Abdu Musubire, MD</last_name>
      <phone>256 77 266 6139</phone>
      <email>amusubire@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

